Trial Profile
Retrospective study of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 May 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium
- 30 Aug 2018 New trial record